In patients with chronic heart failure, the combined application of an ACE1 inhibitor (enalapril) and losartan for 16 weeks significantly reduced plasma insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), TNF-α, interleukin-6, and MCP-1 levels. This evidence concerns the gene INS and Insulin resistance.